Showing results (381-390 of 732) with videos related to

Sort By:
Pageof 74
Nature Communications|August 5, 2018
Genomic instability in mutant p53 cancer cells upon entotic engulfmentHannah L Mackay, David Moore, Callum Hall, et al.
Cell Reports. Medicine|October 14, 2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Genome Biology|August 28, 2014
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionRosalie Fisher, Stuart Horswell, Andrew Rowan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelNicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
The Lancet. Oncology|May 13, 2023
Utility of polygenic risk scores in UK cancer screening: a modelling analysisCatherine Huntley, Bethany Torr, Amit Sud, et al.
Nature|September 9, 2021
Using DNA sequencing data to quantify T cell fraction and therapy responseRobert Bentham, Kevin Litchfield, Thomas B K Watkins, et al.
BMC Medical Genomics|October 3, 2015
TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimenAndrea Marion Marquard, Nicolai Juul Birkbak, Cecilia Engel Thomas, et al.
Nature|September 6, 2013
HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesisCarrie A Adelman, Rafal L Lolo, Nicolai J Birkbak, et al.
Cancer Discovery|January 18, 2014
Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolutionSally M Dewhurst, Nicholas McGranahan, Rebecca A Burrell, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.
Pageof 74